Entest BioMedical's Zander Therapeutics Unit Files Patent Application on Ex Vivo Activated Autologous Immune Cells
Entest BioMedical Inc.'s (OTC: ENTBD) Zander Therapeutics unit announced today its personalized canine cancer immune therapy platform and proof-of-concept experimental data. The data on which this provisional patent was based came from previous research conducted by Thomas Ichim, PhD, a scientific consultant to Zander. On July 31, 2015, Zander filed a provisional patent application with the United States Patent Office (USPTO) on intellectual property in the veterinary oncology space.
Entest BioMedical Inc.'s Zander Therapeutics Unit: Initial Focus is Small Molecule and Cancer Stem Targeting for Veterinary Oncology
Zander Therapeutics, a subsidiary of Entest BioMedical Inc. (OTC: ENTBD), announced today its canine cancer therapeutics and feline leukemia platforms. These platforms will focus on adopting cutting edge technologies such as immune-oncology, small molecule, gene silencing and cancer stem cell targeting for the treatment of cancer in dogs and leukemia in cats.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is a subsidiary of Entest Group Inc. a fully reporting and trades publicly under the symbol: ETNI Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017